Keith Baker Buys 5,000 Shares of Kineta, Inc. (NASDAQ:KA) Stock

Kineta, Inc. (NASDAQ:KAGet Free Report) CFO Keith Baker acquired 5,000 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were bought at an average price of $2.13 per share, for a total transaction of $10,650.00. Following the acquisition, the chief financial officer now directly owns 16,880 shares of the company’s stock, valued at approximately $35,954.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kineta Price Performance

NASDAQ KA traded up $0.17 during mid-day trading on Tuesday, hitting $2.38. The company’s stock had a trading volume of 30,485 shares, compared to its average volume of 22,090. The company’s 50 day simple moving average is $2.11 and its 200 day simple moving average is $3.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.39 and a current ratio of 1.39. Kineta, Inc. has a twelve month low of $1.78 and a twelve month high of $15.54.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Kineta in a report on Monday, August 21st.

Read Our Latest Stock Analysis on Kineta

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Artal Group S.A. bought a new position in shares of Kineta in the fourth quarter valued at approximately $197,000. Renaissance Technologies LLC bought a new position in Kineta during the 4th quarter valued at $111,000. CIBC Asset Management Inc purchased a new position in Kineta during the 1st quarter worth $45,000. Geode Capital Management LLC purchased a new position in Kineta during the 1st quarter worth $34,000. Finally, BlackRock Inc. grew its stake in shares of Kineta by 236.4% in the 2nd quarter. BlackRock Inc. now owns 20,741 shares of the company’s stock worth $54,000 after acquiring an additional 14,575 shares in the last quarter. 13.66% of the stock is currently owned by institutional investors and hedge funds.

Kineta Company Profile

(Get Free Report)

Kineta, Inc, a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.

Featured Stories

Insider Buying and Selling by Quarter for Kineta (NASDAQ:KA)

Receive News & Ratings for Kineta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kineta and related companies with's FREE daily email newsletter.